Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences equity method & fair value option biotech investments carrying value ($M) ($M)
Form 10-Q / 10-K Note 3 Fair Value & Note 4 Equity Securities
Latest, Q2 2026
295
Period ended Jun 30, 2026
Change on a year earlier
-20.1%
369 in Q2 2025
History
12 quarters
Since Q4 2022
Sources
11
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Equity method & fair value option biotech investments carrying value ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 295 | -20.1% | Form 10-Q (filed 2026-08-06) ↗ |
| Q1 2026 | Mar 31, 2026 | 308 | -14.2% | Form 10-Q (filed 2026-05-07) ↗ |
| Q4 2025 | Dec 31, 2025 | 393 | +1.8% | Form 10-Q (filed 2026-08-06) ↗ |
| Q3 2025 | Sep 30, 2025 | 393 | +2.9% | Form 10-Q (filed 2025-11-07) ↗ |
| Q2 2025 | Jun 30, 2025 | 369 | -1.9% | Form 10-Q (filed 2025-08-07) ↗ |
| Q1 2025 | Mar 31, 2025 | 359 | 0.0% | Form 10-Q (filed 2025-05-07) ↗ |
| Q4 2024 | Dec 31, 2024 | 386 | +13.5% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2024 | Sep 30, 2024 | 382 | – | Form 10-Q (filed 2024-11-12) ↗ |
| Q2 2024 | Jun 30, 2024 | 376 | – | Form 10-Q (filed 2024-08-08) ↗ |
| Q1 2024 | Mar 31, 2024 | 359 | – | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2023 | Dec 31, 2023 | 340 | -19.6% | Form 10-K (filed 2025-02-28) ↗ |
| Q4 2022 | Dec 31, 2022 | 423 | – | Form 10-K (filed 2024-02-23) ↗ |
Breakdown
What makes up equity method & fair value option biotech investments carrying value ($m)
- Equity method investment in Arcus Biosciences, Inc. — Fair value carrying amount ($M)969 · Q2 2026
- Equity method investment in Galapagos NV / Lakefront Biotherapeutics NV — Fair value carrying amount ($M)500 · Q2 2026
- Other equity method investments (incl. Assembly Biosciences) — Fair value carrying amount ($M)171 · Q2 2026
Cite this data
StockData. (2026). Gilead Sciences Equity method & fair value option biotech investments carrying value ($M) ($M), quarterly Q4 2022–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/eq_method_carrying
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.